Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
Combining CAR-T therapy with a targeted drug achieves strong responses in hard-to-treat blood cancers, offering a promising two-pronged approach for patients who've exhausted other options.
Lisocabtagene maraleucel (liso-cel) combined with ibrutinib achieved high response rates in relapsed/refractory CLL/SLL in the TRANSCEND CLL 004 trial, supporting CAR-T plus BTK inhibitor combination as a new therapeutic paradigm for this high-unmet-need population. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective non-randomized Phase 2 clinical trial (primary results)
- Category
- hematologic_malignancies
- Maturity
- Potentially Practice-Changing
- Journal
- Blood
Why it surfaced
Landmark primary results from a multicenter Phase 2 trial of CAR-T + BTKi combination in R/R CLL/SLL published in Blood. Directly actionable clinical data for hematologic malignancy watchlist; potential practice-changing implications for CLL management after BTKi/BCL-2 failure.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.